$1.84
-0.10(-4.90%)
Mkt Cap $78M
$1.44
$4.18
52-Week Range
At A Glance
1
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding.
2
Most recently: , including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for t (2026-02-03).
$78M
Market Cap
—
Revenue
-$21M
Net Income
Employees23
Fundamentals
How The Business Makes Money
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001819411
ISINUS36269B1052
CUSIP36269B105
Phone301 500 1556
Address4800 Montgomery Lane, Bethesda, MD, 20814, US
SEC EDGAR